Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Leukemia/Lymphoma

RSS  

Articles

  • Clinical Briefs in Primary Care Supplement

  • Axitinib for Advanced Renal Cell Carcinoma

    This randomized, controlled, open-label, multicenter Phase 3 trial compared axitinib with sorafenib as second-line therapy for metastatic renal clear-cell cancer. The results showed that axitinib extended progression-free survival by 2 months more than sorafenib (6.7 months vs 4.7 months), and had a superior objective response rate (19.4% vs 9.4%).
  • Clinical Briefs in Primary Care Supplement

  • Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer

    In a prospective trial conducted from 2004-2010, 21 patients (median age 65 years) with a clinical complete response after chemoradiotherapy were followed closely per a stringent wait-and-see policy consisting of MRI, endosopies, and CT scans. These patients were compared to 20 patients prospectively who underwent surgery and were found to have a pathologic complete response.
  • Aspirin Reduces Colorectal Cancer Occurrence in Patients with Lynch Syndrome: Implications for Cancer Prevention

    Long-term follow-up of Lynch syndrome patients who completed 2 years of treatment (aspirin or placebo) on the CAPP2 colorectal cancer prevention trial revealed a significant reduction in colorectal cancer development. This was the first large-scale colon cancer prevention trial using aspirin as an intervention. Implications for the prevention of sporadic colon cancer remain conjectural, however tempting it is to extrapolate these findings to the general adult population.
  • Pharmacology Watch

    New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
  • Management of an Asymptomatic Renal Mass in a 78-Year-Old Man with Comorbidities

    An asymptomatic 78-year-old retired accountant presented to his physician with intractable hiccups. Physical examination, complete blood count, and imaging studies did not reveal a cause of the hiccups, and after several days the symptom disappeared. However, upon review of the abdominal CT scan obtained in evaluation of the hiccups, a right renal mass was defined.
  • Absent Influenza Vaccine Response in Rituximab-treated Lymphoma Patients

    Influenza remains a major source of morbidity and increased mortality among patients with cancer, and prior studies had indicated impaired response to vaccination. In the current report, lymphoma patients treated with rituximab, either in combination with chemotherapy or as a single agent, were found to have markedly deficient influenza vaccine response, with not 1 of 67 achieving a protective titer, compared with 42 of 51 controls. Thus, rituximab-treated lymphoma patients are particularly susceptible to vaccine failure and influenza infection should be highly considered in symptomatic patients, even in those who had been appropriately vaccinated.
  • Promising Results with Dasatinib Added to Docetaxel for Treating Castration-resistant Prostate Cancer

    The tyrosine kinase inhibitor dasatinib was added to docetaxel in the treatment of advanced castration-resistant prostate cancer in a Phase 1-2 trial. The combination was shown to be generally well-tolerated and to result in markers of reduced bone turnover in the great majority of patients and in durable PSA responses in approximately 50%. The findings justify proceeding to Phase 3 clinical trial.
  • Synchronous Breast Cancer

    For patients who have synchronous bilateral breast cancer, overall survival has been shown to be less favorable than for patients presenting with unilateral disease. In the current matched case-control series, overall survival was comparable. Clinicians are advised to prescribe systemic therapy based upon the more aggressive of the two lesions.